CA
NZ
UK
AU
IND
US
…
Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. Its pipeline includes Plozasiran to reduce production of apolipoprotein C-III in Phase 3 studies; Zodasiran to reduce production of angiopoietin-like protein 3 in Phase 3 clinical trials; ARO-DIMER-PA, a dual functional RNAi molecule in a Phase 1/2a clinical trials; and ARO-PNPLA3, an investigational RNAi therapeutic in Phase 1 clinical trials. The company also develops ARO-INHBE, to reduce the hepatic expression of the INHBE gene and its secreted gene product, Activin E in Phase 1/2a clinical trials; ARO-ALK7 to silence adipocyte expression of the ACVR1C gene in Phase 1/2a clinical trials; ARO-RAGE to reduce production of the receptor for advanced glycation end products in Phase 1/2a clinical trials; and ARO-MAPT, an investigational RNAi-based therapy. In addition, it is developing ARO-C3 to reduce production of C3 in Phase 1/2a clinical trials; and ARO-CFB to reduce hepatic expression of CFB in a Phase 1/2a clinical trials. The company has collaboration and license Agreements with Glaxosmithkline Intellectual Property (No. 3) Limited; Takeda Pharmaceutical Company Limited; Amgen Inc.; and Sarepta Therapeutics, Inc. Arrowhead Pharmaceuticals, Inc. was founded in 2003 and is headquartered in Pasadena, California.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
Arrowhead Pharmaceuticals is a clinical-stage biotech developing RNA interference therapies, primarily for liver-targeted diseases using its delivery platform. Long-term growth may be driven by successful clinical readouts, regulatory approvals and strategic partnerships, and investors may find appeal in the platform-based pipeline's commercialization potential.
Principal risks are clinical and regulatory setbacks, sustained cash burn that could require dilutive financing and intense competition within RNA therapeutics.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
| Breakdown | 2025-09-30 | 2024-09-30 | 2023-09-30 | 2022-09-30 | 2021-09-30 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-09-30 | 2024-09-30 | 2023-09-30 | 2022-09-30 | 2021-09-30 |
| Income before tax | 51.53M | -612.46M | -206.49M | -172.71M | -140.85M |
| Minority interest | -31.75M | 10.20M | 4.00M | -0.43M | - |
| Net income | -1.63M | -599.49M | -205.28M | -176.49M | -140.85M |
| Selling general administrative | 123.94M | 96.82M | 92.55M | 124.43M | 80.98M |
| Selling and marketing expenses | - | 1.94M | - | - | - |
| Gross profit | 805.52M | -15.04M | 240.74M | 243.23M | 138.29M |
| Reconciled depreciation | 23.93M | 18.59M | 12.49M | 10.42M | 8.27M |
| Ebit | 140.89M | -580.11M | -200.66M | -188.93M | -149.04M |
| Ebitda | 164.82M | -561.51M | -188.16M | -178.51M | -140.77M |
| Depreciation and amortization | 23.93M | 18.59M | 12.49M | 10.42M | 8.27M |
| Non operating income net other | - | - | - | 0.77M | 2.07M |
| Operating income | 98.35M | -601.08M | -205.00M | -178.51M | -149.04M |
| Other operating expenses | 731.10M | 604.63M | 445.74M | 421.74M | 287.32M |
| Interest expense | 89.36M | 32.35M | 18.33M | 5.03M | 6.12M |
| Tax provision | 21.42M | -2.77M | 2.78M | 3.79M | 0.00M |
| Interest income | 37.29M | 22.72M | 15.30M | - | - |
| Net interest income | -52.07M | -9.63M | -3.03M | 5.03M | 6.12M |
| Income tax expense | 21.42M | -2.77M | 2.78M | 3.79M | 0.00M |
| Total revenue | 829.45M | 3.55M | 240.74M | 243.23M | 138.29M |
| Total operating expenses | 707.17M | 586.04M | 445.74M | 421.74M | 287.32M |
| Cost of revenue | 23.93M | 18.59M | - | - | - |
| Total other income expense net | -46.81M | -11.38M | 1.54M | 5.80M | 8.19M |
| Net income from continuing ops | 30.11M | -609.69M | -209.28M | -172.71M | -140.85M |
| Net income applicable to common shares | - | - | - | -176.06M | -140.85M |
| Breakdown | 2025-09-30 | 2024-09-30 | 2023-09-30 | 2022-09-30 | 2021-09-30 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-09-30 | 2024-09-30 | 2023-09-30 | 2022-09-30 | 2021-09-30 |
| Total assets | 1385.30M | 1139.80M | 765.55M | 691.94M | 710.15M |
| Intangible assets | 6.86M | 8.56M | 10.26M | 11.96M | 13.66M |
| Other current assets | 24.45M | 14.51M | 7.08M | 20.20M | 2.19M |
| Total liab | 881.88M | 948.74M | 478.39M | 585.98M | 301.33M |
| Total stockholder equity | 466.05M | 185.44M | 271.34M | 105.96M | 408.82M |
| Other current liab | 128.12M | 85.44M | -46.43M | -5.64M | 23.77M |
| Common stock | 0.23M | 0.22M | 0.20M | 105.96M | 0.20M |
| Capital stock | 0.23M | 0.22M | 0.20M | 105.96M | 0.20M |
| Retained earnings | -1627.15M | -1625.52M | -1026.03M | -820.75M | -644.69M |
| Other liab | - | - | - | 55.95M | 190.27M |
| Other assets | - | - | - | 0.22M | 96.76M |
| Cash | 226.55M | 102.69M | 110.89M | 108.00M | 184.43M |
| Total current liabilities | 195.49M | 103.17M | 0.87M | 74.10M | 146.54M |
| Current deferred revenue | 2.40M | - | 0.87M | 74.10M | 111.06M |
| Net debt | 139.74M | 14.68M | 4.28M | -26.43M | -158.89M |
| Short term debt | 47.29M | 6.34M | 10.56M | 2.78M | 2.25M |
| Short long term debt | 40.00M | - | - | - | - |
| Short long term debt total | 366.28M | 117.37M | 115.17M | 81.58M | 25.55M |
| Other stockholder equity | 2086.53M | 1806.00M | 1300.39M | 820.89M | 1053.39M |
| Property plant equipment | - | - | - | 110.30M | 48.67M |
| Total current assets | 950.64M | 695.47M | 110.89M | 376.40M | 384.60M |
| Long term investments | - | - | 292.74M | 105.87M | 245.59M |
| Net tangible assets | - | - | - | 398.52M | 395.16M |
| Short term investments | 692.82M | 578.28M | 292.74M | 268.39M | 183.35M |
| Net receivables | 6.82M | - | 0.00M | 1.41M | 10.26M |
| Long term debt | 214.88M | 393.18M | - | - | - |
| Inventory | - | - | - | -21.61M | 4.36M |
| Accounts payable | 17.67M | 11.39M | 35.87M | 2.87M | 9.46M |
| Noncontrolling interest in consolidated entity | - | - | - | 19.82M | - |
| Accumulated other comprehensive income | 6.44M | 4.75M | -3.22M | -0.14M | -0.07M |
| Common stock total equity | - | - | - | 0.20M | 0.20M |
| Retained earnings total equity | - | - | - | -820.75M | -644.69M |
| Non currrent assets other | 1.39M | 4.48M | 361.93M | 29.12M | 0.27M |
| Non current assets total | 434.66M | 444.33M | 654.66M | 315.54M | 325.55M |
| Capital lease obligations | 111.40M | 117.37M | 115.17M | 81.58M | 25.55M |
| Breakdown | 2025-09-30 | 2024-09-30 | 2023-09-30 | 2022-09-30 | 2021-09-30 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-09-30 | 2024-09-30 | 2023-09-30 | 2022-09-30 | 2021-09-30 |
| Investments | -129.29M | -420.07M | -96.16M | 47.36M | -118.11M |
| Change to liabilities | - | - | - | 11.23M | 13.38M |
| Total cashflows from investing activities | -129.29M | -420.07M | - | -5.42M | -141.68M |
| Net borrowings | -191.37M | 392.00M | - | - | - |
| Total cash from financing activities | 74.01M | 870.52M | 253.05M | 65.19M | 11.30M |
| Change to operating activities | - | - | - | 11.95M | 10.39M |
| Net income | 30.11M | -609.69M | -209.28M | -176.49M | -140.85M |
| Change in cash | 123.86M | -8.21M | 2.89M | -76.43M | 40.85M |
| Begin period cash flow | 102.69M | 110.89M | 108.00M | 184.43M | 143.58M |
| End period cash flow | 226.55M | 102.69M | 110.89M | 108.00M | 184.43M |
| Total cash from operating activities | 179.55M | -462.85M | -153.89M | -136.13M | 171.22M |
| Issuance of capital stock | 241.39M | 429.26M | - | 0.00M | 0.00M |
| Depreciation | 23.93M | 18.59M | 12.49M | 10.42M | 8.27M |
| Change to inventory | - | - | -3.36M | - | 9.16M |
| Change to account receivables | -56.97M | 0.00M | 1.41M | 8.85M | -9.41M |
| Sale purchase of stock | - | - | - | 5.19M | 11.30M |
| Other cashflows from financing activities | -5.00M | 46.87M | 253.05M | 60.00M | 11.30M |
| Change to netincome | - | - | - | 125.33M | 76.67M |
| Capital expenditures | 22.67M | 141.47M | 176.74M | 52.78M | 23.57M |
| Change receivables | - | - | - | 8.85M | -9.41M |
| Cash flows other operating | - | - | - | -118.36M | 222.90M |
| Cash and cash equivalents changes | - | - | - | -76.36M | 40.85M |
| Change in working capital | -18.23M | 25.09M | -51.55M | -98.29M | 226.87M |
| Stock based compensation | 63.37M | 73.97M | 78.13M | 120.89M | 76.67M |
| Other non cash items | 80.38M | 29.19M | 50.72M | 7.34M | 0.27M |
| Free cash flow | 156.89M | -604.32M | -330.63M | -188.91M | 147.66M |
Sector: Healthcare Industry: Biotechnology
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| ARWR Arrowhead Pharmaceuticals Inc |
-0.59 0.98% |
59.90 | 43.32 | 111.11 | 9.12 | 17.50 | 8.57 | 25.24 |
| NVO Novo Nordisk A/S |
0.86 2.20% |
40.00 | 41.58 | 31.15 | 2.13 | 32.99 | 2.11 | 4.70 |
| VRTX Vertex Pharmaceuticals Inc |
18.88 3.50% |
558.88 | 30.22 | 24.27 | 10.36 | 6.50 | 9.99 | 24.66 |
| REGN Regeneron Pharmaceuticals Inc |
109.12 13.33% |
927.89 | 29.07 | 20.12 | 7.57 | 3.82 | 6.95 | 19.42 |
| ARGNF argenx SE |
- -% |
900.30 | 45.77 | 31.25 | 13.84 | 7.12 | 11.38 | 36.06 |
Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. Its pipeline includes Plozasiran to reduce production of apolipoprotein C-III in Phase 3 studies; Zodasiran to reduce production of angiopoietin-like protein 3 in Phase 3 clinical trials; ARO-DIMER-PA, a dual functional RNAi molecule in a Phase 1/2a clinical trials; and ARO-PNPLA3, an investigational RNAi therapeutic in Phase 1 clinical trials. The company also develops ARO-INHBE, to reduce the hepatic expression of the INHBE gene and its secreted gene product, Activin E in Phase 1/2a clinical trials; ARO-ALK7 to silence adipocyte expression of the ACVR1C gene in Phase 1/2a clinical trials; ARO-RAGE to reduce production of the receptor for advanced glycation end products in Phase 1/2a clinical trials; and ARO-MAPT, an investigational RNAi-based therapy. In addition, it is developing ARO-C3 to reduce production of C3 in Phase 1/2a clinical trials; and ARO-CFB to reduce hepatic expression of CFB in a Phase 1/2a clinical trials. The company has collaboration and license Agreements with Glaxosmithkline Intellectual Property (No. 3) Limited; Takeda Pharmaceutical Company Limited; Amgen Inc.; and Sarepta Therapeutics, Inc. Arrowhead Pharmaceuticals, Inc. was founded in 2003 and is headquartered in Pasadena, California.
177 East Colorado Boulevard, Pasadena, CA, United States, 91105
626 304 3400
711
| Name | Title | Year Born |
|---|---|---|
| Dr. Christopher R. Anzalone Ph.D. | CEO, Pres & Director | 1969 |
| Mr. Kenneth A. Myszkowski | Chief Financial Officer | 1966 |
| Mr. Patrick O'Brien J.D., PharmD | COO & Gen. Counsel | 1964 |
| Dr. James C. Hamilton M.D., MBA | Sr. VP of Discovery & Translational Medicine | 1979 |
| Dr. Javier San Martin M.D. | Chief Medical Officer | 1965 |
| Dr. Mark M. Davis Ph.D. | Founder and Founder & Director of Insert Therapeutics Inc & Calando | NA |
| Dr. Vincent Anzalone CFA | Head of Investor Relations & VP | NA |
| Mr. Howard Lovy | Director of Communications | NA |
| Dr. Mark Seefeld | Head of Toxicology & VP | 1954 |
| Ms. Tracie Oliver | Chief Commercial Officer | NA |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.
Download a free report with stock ideas and industry insights for general information.
Download Free Report Now →
Basic Materials
-1.82%
Communication Services
-0.22%
Consumer Cyclical
-0.13%
Consumer Defensive
+0.32%
Energy
+0.15%
Financial Services
-0.85%
Financials
+2.34%
Healthcare
-1.28%
Industrials
-0.96%
Real Estate
-0.38%
Technology
-2.73%
Utilities
-0.31%
Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.
Portfolio
Watchlist
Please wait processing your request...